Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2023-02-23 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
关于增加公司注册资本、变更公司注册地址并修订公司章程的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Yunnan Watson Biotechnology Co., Ltd. regarding changes in the company's registered capital, change of registered address, and amendments to the company's articles of association. It includes specifics about the increase in registered capital due to stock option exercises, the new company address, and extensive revisions to the company's bylaws. The content is regulatory in nature, focusing on corporate governance and compliance with laws and stock exchange rules. It does not contain financial statements, audit opinions, earnings data, or meeting minutes. It is not a report of voting results or a proxy solicitation. The document is a formal announcement of corporate changes and governance updates, fitting best under Regulatory Filings (RNS) as it does not fit the more specific categories like Board/Management Information (MANG) which typically covers personnel changes, or Share Issue/Capital Change (SHA) which usually covers new share issues or stock splits rather than capital increase due to option exercises and related governance amendments. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-02-23 Chinese
关于子公司对外捐赠的公告
Board/Management Information Classification · 95% confidence The document is a public announcement by a company about a donation made by its subsidiary. It details the board meeting resolutions approving the donation, the purpose and impact of the donation, and opinions from independent directors and the supervisory board. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no reference to any report publication. The content is about a corporate social responsibility action approved by the board, which is a management or board announcement. It does not fit into financial reports, earnings releases, or regulatory filings. Therefore, the best fitting category is 'Board/Management Information' (MANG), as it announces a board-approved management decision regarding a donation.
2023-02-23 Chinese
公司章程（2023年2月）
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of 云南沃森生物技术股份有限公司 dated February 2023. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, share transfer, shareholder meetings, voting procedures, and other governance-related rules. There is no financial data, earnings information, audit results, or capital raising updates. The content is focused on the internal rules and governance framework of the company. This matches the definition of Governance Information (CGR), which covers the company's internal rules, board structure, and governance practices.
2023-02-23 Chinese
关于公司董事长及其控制的企业增持公司股份计划实施过半的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the progress of a share increase plan by the company's chairman and related entities. It details the number of shares acquired, the amount spent, the purpose of the share increase, and the implementation period. It does not contain financial statements or comprehensive financial data but focuses on shareholding changes by insiders. This fits the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives. The document length is 2480 characters, which is relatively short and focused on share transactions rather than a full financial report or other types of filings.
2023-02-17 Chinese
2022年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2022 annual performance forecast (业绩预告) from Yunnan Watson Biotechnology Co., Ltd. It provides estimated financial results for the full year 2022, including net profit and revenue projections, but it is explicitly stated that the data is preliminary, unaudited, and subject to final disclosure in the 2022 Annual Report. The document is short (1227 characters) and serves as an earnings forecast rather than a full financial report. This fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only, not a full annual report (10-K). FY 2022
2023-01-29 Chinese
关于公司办公地址变更的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (656 characters) about the company's change of office address and postal code. It contains no financial data, no discussion of financial results, no regulatory certifications, or voting results. It is not a report or a presentation but a simple corporate information update. Therefore, it does not fit into categories like Annual Report, Interim Report, or Management Reports. It is a general regulatory announcement about company information change, which fits best under Regulatory Filings (RNS).
2023-01-16 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.